[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts

Kamille Dumong Erichsen; Camilla Bardram Johnbeck; Fredrik Björkling; Jacob Madsen; Michael Bzorek; Peter Buhl Jensen; Liselotte Højgaard; Maxwell Sehested; Andreas Kjær; Mette Munk Jensen

doi:10.1371/journal.pone.0053410

[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts

Kamille Dumong Erichsen, Camilla Bardram Johnbeck, Fredrik Björkling, Jacob Madsen, Michael Bzorek, Peter Buhl Jensen, Liselotte Højgaard, Maxwell Sehested, Andreas Kjær, Mette Munk Jensen

Research output: Contribution to journal › Journal article › Research › peer-review

23 Citations (Scopus)

Abstract

APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.

Original language	English
Article number	e53410
Journal	P L o S One
Volume	8
Issue number	1
Pages (from-to)	1-8
Number of pages	9
ISSN	1932-6203
DOIs	https://doi.org/10.1371/journal.pone.0053410
Publication status	Published - 2013

Access to Document

10.1371/journal.pone.0053410

Cite this

Erichsen, K. D., Johnbeck, C. B., Björkling, F., Madsen, J., Bzorek, M., Jensen, P. B., Højgaard, L., Sehested, M., Kjær, A., & Jensen, M. M. (2013). [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts. P L o S One, 8(1), 1-8. [e53410]. https://doi.org/10.1371/journal.pone.0053410

[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts. / Erichsen, Kamille Dumong; Johnbeck, Camilla Bardram; Björkling, Fredrik; Madsen, Jacob; Bzorek, Michael; Jensen, Peter Buhl ; Højgaard, Liselotte; Sehested, Maxwell; Kjær, Andreas ; Jensen, Mette Munk.

In: P L o S One, Vol. 8, No. 1, e53410, 2013, p. 1-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Erichsen, KD, Johnbeck, CB, Björkling, F, Madsen, J, Bzorek, M, Jensen, PB , Højgaard, L, Sehested, M, Kjær, A & Jensen, MM 2013, '[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts', P L o S One, vol. 8, no. 1, e53410, pp. 1-8. https://doi.org/10.1371/journal.pone.0053410

Erichsen, Kamille Dumong ; Johnbeck, Camilla Bardram ; Björkling, Fredrik ; Madsen, Jacob ; Bzorek, Michael ; Jensen, Peter Buhl ; Højgaard, Liselotte ; Sehested, Maxwell ; Kjær, Andreas ; Jensen, Mette Munk. / [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts. In: P L o S One. 2013 ; Vol. 8, No. 1. pp. 1-8.

@article{b1ca91311b3640d28308e9c06134f07c,

title = "[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts",

abstract = "APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.",

author = "Erichsen, {Kamille Dumong} and Johnbeck, {Camilla Bardram} and Fredrik Bj{\"o}rkling and Jacob Madsen and Michael Bzorek and Jensen, {Peter Buhl} and Liselotte H{\o}jgaard and Maxwell Sehested and Andreas Kj{\ae}r and Jensen, {Mette Munk}",

year = "2013",

doi = "10.1371/journal.pone.0053410",

language = "English",

volume = "8",

pages = "1--8",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "1",

}

TY - JOUR

T1 - [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts

AU - Erichsen, Kamille Dumong

AU - Johnbeck, Camilla Bardram

AU - Björkling, Fredrik

AU - Madsen, Jacob

AU - Bzorek, Michael

AU - Jensen, Peter Buhl

AU - Højgaard, Liselotte

AU - Sehested, Maxwell

AU - Kjær, Andreas

AU - Jensen, Mette Munk

PY - 2013

Y1 - 2013

N2 - APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.

AB - APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.

U2 - 10.1371/journal.pone.0053410

DO - 10.1371/journal.pone.0053410

M3 - Journal article

C2 - 23308217

VL - 8

SP - 1

EP - 8

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 1

M1 - e53410

ER -